Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia (STO)

• ClinicalTrials.gov Identifier: NCT01599286
• Recruitment Status: Completed
• First Posted: May 16, 2012
• Results First Posted: February 15, 2021
• Last Update Posted: February 15, 2021
• Sponsor: Mendel Tuchman
• Collaborators: Children's National Research Institute; Boston Children's Hospital; University Hospitals Cleveland Medical Center; University of California, Los Angeles; Children's Hospital of Philadelphia; Stanford University; Icahn School of Medicine at Mount Sinai; University of Pittsburgh; Children's Hospital Colorado
• Information provided by (Responsible Party): Mendel Tuchman, Children's National Research Institute

Study Description

Brief Summary:

The overall objective of this drug trial is to determine whether the treatment of acute hyperammonemia with N-carbamyl-L-glutamate (NCG, Carglumic acid) in propionic acidemia (PA), methylmalonic acidemia (MMA), late-onset CPS1 deficiency (CPSD) and late-onset Ornithine transcarbamylase deficiency (OTCD) accelerates the resolution of hyperammonemia efficiently and safely.

The primary goal is to determine if the study drug (NCG) efficiently reduces ammonia levels following a hyperammonemia episode(s).

Secondly, the investigators want to know if treatment with this study drug (NCG) efficiently improves neurologic function, reduces plasma glutamine levels and lessens the duration of hospitalization after each episode of hyperammonemia.

Condition or disease	Intervention/treatment	Phase
Propionic Acidemia, Type I and/or Type II; Methylmalonic Acidemia; Carbamoyl-Phosphate Synthase I Deficiency Disease; Ornithine Carbamoyltransferase Deficiency	Drug: Carbaglu; Drug: Placebo	Phase 2

Detailed Description:

This is a double-blind, placebo-controlled, randomized clinical drug trial to evaluate the efficacy of NCG in the treatment of two organic acidemias (severe PA and MMA), and two urea-cycle disorders (late-onset CPSD and OTCD).

Primarily, the investigators want to determine whether NCG treatment of acute hyperammonemia in severe, neonatal-onset PA, MMA, CPSD, and OTCD is efficacious and whether it is safe. The investigators will approach this task in two ways.

1. Assess Whether NCG Treatment is Effective

   The objective of this study is to assess whether NCG is efficacious in treating hyperammonemia and improving outcome:

   The investigators will realize this goal by randomizing each hyperammonemic episode from every subject to NCG (NCG)+standard treatment (NCG-STD) versus placebo+standard treatment (PLBO-STD) and subsequently gauging response with the primary outcome of plasma ammonia levels, in addition to the plasma glutamine, the Functional Status Scale, and the length of hospitalization.

2. Safety

The primary safety outcome of the study will be the assessed via the rate of Serious Adverse Events (SAEs), defined in this study as death or substantial prolongation of hospitalization, as patients are hospitalized as part of the entry to the study.

Safety tests consisting of complete blood count (CBC), liver and kidney function tests, and coagulation profile (PTT/INR) will be performed before treatment, between days 3-5 of treatment, and just prior to discontinuation of NCG. An electrocardiogram will be performed before treatment and on the third day of treatment or before discharge if earlier.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 35 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia
• Actual Study Start Date: September 1, 2012
• Actual Primary Completion Date: April 30, 2019
• Actual Study Completion Date: April 30, 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: Active Comparator; Parallel Trial Comparing NCG + Standard of Care Treatment	Drug: Carbaglu; Carbaglu Chemical Composition: N-carbamoyl-L-glutamic acid (NCG) The daily dose will be 150 mg/kg/ day or 3.3 g/m2/day for patients >15 kg and will be administered for 7 days or until discharge, whichever is sooner. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube. Standard of care will prevail when choosing the mode of drug administration. The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast-push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste.; Other Name: Carglumic Acid
Active Comparator: Placebo Comparator; Placebo and Standard of Care Therapy	Drug: Placebo; Placebo that looks/tastes the same as NCG and is administered on the same schedule as the NCG intervention

Outcome Measures

Primary Outcome Measures :

1. Time to the Primary Outcome (Earlier of Ammonia <50 µmol/L or Hospital Discharge) [ Time Frame: Average of all measurements of hyperammonemia, for up to 7 days ]
   The composite primary intention to treat (ITT) outcome of the earlier of time to reach an ammonia level of ≤50 µmol/L or hospital discharge. Data presented as a hazard ratio based on the time to reach an ammonia level of ≤50 µmol/L. The outcome measure was a survival analysis based on time to reach the earlier of an ammonia level of ≤50 µmol/L or time to discharge, which was considered to be a point where the patient was no longer at risk of neurological injury from ammonia. The outcome of survival analysis was a hazard ratio reflecting the ratio of probabilities in each group (drug vs placebo) of reaching the earlier of an ammonia level of ≤50 µmol/L or discharge. We measured multiple post-treatment ammonia levels at uncontrolled times during an episode, so it is difficult to compute a meaningful average that would not be biased by the frequency and timing of ammonia testing during episodes.

Eligibility Criteria

• Ages Eligible for Study: 1 Week to 99 Years (Child, Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria

o Aged older than 1 week with an established diagnosis of CPSD or OTCD (as follows):

• Diagnosed with late-onset CPSD confirmed by detection of pathogenic mutation(s), and/or decreased (<20% of control) CPS enzyme activity in liver OR
• Diagnosed with late-onset OTCD by detection of pathogenic OTC mutation, OR decreased (<20% of control) OTC enzyme activity in liver OR elevated urinary orotate (greater than 20 µM/mM) following allopurinol loading with the absence of argininosuccinic acid

AND: Subject or subject's first-degree relative had plasma ammonia level ≥100 μmol/L >1 week of age

OR

o An established diagnosis of PA or MMA (as follows):

- Diagnosed with PA by semi-quantitative urine organic acid analysis, defined as the presence of elevated Methylcitric acid and normal methylmalonic acid levels and no evidence of biotin related disorders in the organic acid analysis

OR

- Diagnosed with MMA by semi-quantitative urine organic acid analysis, defined as an elevation of methylmalonic acid and no evidence of vitamin B12 dependent disorder on plasma amino acid analysis (B12 dependency is defined by documented B12 responsiveness)

AND: Subject or subject's first-degree relative had plasma ammonia level at any time ≥100 μmol/L

• Able to receive medications orally, by nasogastric (NG)-tube or by gastric (G)-tube
• No concomitant illness which would preclude safe participation as judged by the investigator
• If post-menarcheal must have a negative pregnancy test prior to administration of study drug at each episode
• Signed informed consent by the subject or the subject's legally acceptable representative

Exclusion Criteria

• Administration of NCG within 7 days of participation in the study
• Use of any other investigational drug, biologic, or therapy
• Planned participation in any other clinical trial
• Diagnosis of any medical condition causing hyperammonemia which is not PA/MMA, CPSD or OTCD. Other urea cycle disorders will be excluded from this study
• Any clinical or laboratory abnormality or medical condition that, at the discretion of the investigator, may put the subject at additional risk by participating in this study
• Has had a liver transplant
• Is not expected to be compliant with this study in terms of returning to the site for subsequent episodes of hyperammonemia crises
• Is pregnant

Contacts and Locations

Locations

United States, California

University of California Los Angeles

Los Angeles, California, United States, 90095

Lucile Packard Children's Hospital at Stanford

Palo Alto, California, United States, 94304

United States, Colorado

The Children's Hospital of Colorado

Aurora, Colorado, United States, 80045

United States, District of Columbia

Children's National Medical Center

Washington, District of Columbia, United States, 20010

United States, Massachusetts

Children's Hospital Boston

Boston, Massachusetts, United States, 02115

United States, New York

Mount Sinai School of Medicine

New York, New York, United States, 10029

United States, Ohio

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States, 44106

United States, Pennsylvania

The Children's Hospital of Philadelphia (CHOP)

Philadelphia, Pennsylvania, United States, 19104

University of Pittsburgh

Pittsburgh, Pennsylvania, United States, 15224

Sponsors and Collaborators

Mendel Tuchman

Children's National Research Institute

Boston Children's Hospital

University Hospitals Cleveland Medical Center

University of California, Los Angeles

Children's Hospital of Philadelphia

Stanford University

Icahn School of Medicine at Mount Sinai

University of Pittsburgh

Children's Hospital Colorado

Investigators

• Principal Investigator: Mendel Tuchman, MD; Children's National Research Institute

  Study Documents (Full-Text)

Documents provided by Mendel Tuchman, Children's National Research Institute:

Study Protocol and Statistical Analysis Plan  [PDF] May 1, 2020

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Amari S, Shahrook S, Namba F, Ota E, Mori R. Branched-chain amino acid supplementation for improving growth and development in term and preterm neonates. Cochrane Database Syst Rev. 2020 Oct 2;10(10):CD012273. doi: 10.1002/14651858.CD012273.pub2.

• Responsible Party: Mendel Tuchman, Scientific Director, Children's Research Institute, Children's National Research Institute
• ClinicalTrials.gov Identifier: NCT01599286
• Other Study ID Numbers: NCGC0008
• First Posted: May 16, 2012
• Results First Posted: February 15, 2021
• Last Update Posted: February 15, 2021
• Last Verified: January 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No
• Plan Description: This is a blinded study, the individual participant data will not be shared

Keywords provided by Mendel Tuchman, Children's National Research Institute:

Hyperammonemia; Propionic Acidemia (PA); Methylmalonic Acidemia (MMA); Late-Onset CPS1 Deficiency (CPSD); Late-Onset Ornithine Transcarbamylase Deficiency (OTCD); Carbaglu

Additional relevant MeSH terms:

Ornithine Carbamoyltransferase Deficiency Disease; Carbamoyl-Phosphate Synthase I Deficiency Disease; Propionic Acidemia; Acidosis; Deficiency Diseases; Hyperammonemia; Acid-Base Imbalance; Metabolic Diseases; Malnutrition; Nutrition Disorders; Amino Acid Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Pathologic Processes; Urea Cycle Disorders, Inborn; Brain Diseases, Metabolic, Inborn; Brain Diseases, Metabolic; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Genetic Diseases, X-Linked; Mitochondrial Diseases